Thyroid Eye Disease
📧 Sign up to get email alerts when something new happens for Thyroid Eye Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study [Phase 4]
Phase 4 post-marketing requirement study for TEPEZZA (teprotumumab-trbw) in Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: OCT Angiography Drived Alterations in Thyroid-associated Orbitopathy
Completed clinical trial investigating OCT Angiography-derived alterations in Thyroid eye disease (thyroid-associated orbitopathy).
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) [Phase 3]
Phase 3 safety, tolerability and pharmacokinetics study of VRDN-003 in participants with Thyroid Eye Disease; the trial is currently active …
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease [Phase 3]
A Phase 3 trial evaluating batoclimab for active thyroid eye disease has completed.
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) [Phase 3]
A Phase 3 clinical trial THRIVE-2 evaluating Veligrotug (VRDN-001) for chronic Thyroid Eye Disease has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease [Phase 2]
A Phase 2 clinical trial evaluating IBI311 in patients with Thyroid Eye Disease has completed. The update notes the study status but does no…
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
A real-world study completed to evaluate the effectiveness and safety of Teprotumumab in patients with Thyroid Eye Disease.
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) [Phase 3]
A Phase 3 safety, tolerability and efficacy study of Veligrotug (VRDN 001) in healthy volunteers and Thyroid Eye Disease patients (THRIVE) h…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) [Phase 1, Phase 2]
ACELYRIN has completed a Phase 1/2 trial evaluating Lonigutamab for Thyroid Eye Disease, with an update highlighting efficacy and safety asp…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Study of ZB001 in Chinese Patients With Thyroid Eye Disease [Phase 1]
Phase 1 study of ZB001 in Chinese patients with Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]
An extension study of two doses of Linsitinib for Thyroid Eye Disease is in Phase 2/3 and currently recruiting, sponsored by Sling Therapeut…
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) [Phase 3]
A Phase 3 trial evaluating secukinumab 300 mg for Thyroid Eye Disease (Graves' orbitopathy) was terminated, and results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial of LASN01 in healthy subjects and patients with pulmonary fibrosis or thyroid eye disease has completed, assessin…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease [Phase 3]
A Phase 3 multicenter open-label extension study evaluating the efficacy and safety of IBI311 in subjects with Thyroid Eye Disease (TED).
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease [Phase 1]
Phase 1 study evaluating TEPEZZA in participants with Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease [Phase 4]
A Phase 4 study evaluating TEPEZZA (teprotumumab) for chronic inactive thyroid eye disease has been completed, with results posted in April …
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: A Study of IBI311 in Subjects With Active Thyroid Eye Disease [Phase 2, Phase 3]
A phase 2/3 clinical trial update for IBI311 in active thyroid eye disease has been completed.
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease [Phase 2, Phase 3]
A completed Phase 2/3 trial comparing local betamethasone versus triamcinolone injection for thyroid eye disease.
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease [Phase 4]
Phase 4 trial update on hyaluronic acid gels for upper lid retraction in active stage thyroid eye disease; study terminated.
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Celecoxib for Thyroid Eye Disease [Phase 2]
Phase 2 trial of celecoxib for Thyroid Eye Disease was terminated; results were posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study [Phase 3]
A Phase 3 randomized, placebo-controlled trial of teprotumumab infusions in Graves' orbitopathy (thyroid eye disease) completed with results…
-
CLINICAL_TRIALS trial_result · 2018-02-19Clinical Trial Update: Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues [Phase 3]
Phase 3 trial assessing prostaglandin analogue drops for treating soft tissue expansion in inactive thyroid eye disease (thyroid-associated …
-
CLINICAL_TRIALS trial_result · 2017-08-30Clinical Trial Update: Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease [Phase 2]
Phase 2 trial of teprotumumab in active thyroid eye disease completed; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Disappearance of Graves' Orbitopathy
A completed clinical trial by the University of Pisa in Thyroid Eye Disease reports disappearance of Graves' ophthalmopathy.
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) [Phase 3]
Phase 3 trial assessing tocilizumab for Graves' ophthalmopathy (thyroid eye disease) has completed.